Overview

A prospective, single-arm, multicenter, exploratory study to evaluate the efficacy and safety of D-CLAG regimen in the treatment of relapsed or refractory acute myeloid leukemia

Eligibility

Inclusion Criteria:

• Acute myeloid leukemia (non-acute promyelocytic leukemia) must be diagnosed before enrollment. Diagnostic criteria refer to WHO (World Health Organization) classification.
• Refractory or relapsed AML: refractory is defined as the failure of CR after 2 courses of standard induced remission therapy (2 courses of idarubicin+cytarabine (IA) regimen or 1 course of IA regimen + 1 course of high dose cytarabine); Relapse is defined as the blast cells >5% in bone marrow or presence of extramedullary leukemia for patient who achieved CR before.
• Age 18-70.
• Eastern cancer cooperation group (ECOG) 2.
• Creatinine clearance 30 mL/min (estimated glomerular filtration rate (eGFR) according to the Cockcroft-Gault formula or Modification of Diet in Renal Disease (MDRD) formula).
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 3 upper limit of normal range (ULN), total bilirubin 2ULN.
• Echocardiography (ECHO) showed left ventricular ejection fraction (LVEF)50%.
• Life expectancy >8 weeks.
• Voluntarily sign the informed consent and understand and comply with the requirements of the study.

Exclusion Criteria:

• White blood cell (WBC) > 50 * 109 / L
• Patients who have received salvage treatment with D-CLAG.
• Current active cardiovascular disease, such as uncontrolled arrhythmia, uncontrolled hypertension, congestive heart failure, any grade 3 or 4 heart disease according to the New York heart association (NYHA) functional classification, or a history of myocardial infarction within 6 months prior to screening.
• Other serious diseases that may limit patient participation in the trial (e.g. progressive infections, uncontrolled diabetes).
• Pregnant or nursing women.
• Unable to understand or follow the research protocol or unable to sign the informed consent.